drugset
drugset / Trial / NCT03146962

High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies

NCT03146962 ↗

Phase 2 Completed 61 enrolled Weill Medical College of Cornell University Stand Up To Cancer · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, single arm, 3-cohort, open-label trial of high dose Vitamin C intravenous infusion in subjects with solid tumor malignancies who are eligible for resection (cohort A) or with extended RAS (e.g.KRAS or NRAS) or BRAF mutation metastatic cancer who have received prior systemic treatment (cohort B). Cohort C will involve patients with colorectal cancer having an extended RAS or BRAF mutation who are amenable for localregional therapy of hepatic metastases with Yttrium-90 radioembolization.

Timeline

Start
2017-03-29
Primary completion
2023-04-21
Completion
2023-04-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified 0.5 g/kg Intravenous
Subject Vitamin C Other / unclassified 0.75 g/kg Intravenous
Subject Vitamin C Other / unclassified 1 g/kg Intravenous
Subject Vitamin C Other / unclassified 1.25 g/kg Intravenous

Indications

colorectal cancer lung cancer malignant pancreatic neoplasm